What Gives With Portola Pharmaceuticals?
The FDA has surprisingly rejected the company's first commercial drug. Can Portola Pharmaceuticals overcome this setback?
This podcast was recorded on Aug. 24, 2016.
Advertisement
Recommended Stories
Walmart CEO started his career unloading trailers at the warehouse—he says he got promotion after promotion by raising his hand when his boss was out of town
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Fortune•Trump to set interest rates himself under secret presidential plan
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The Telegraph•2 Stock-Split Stocks to Buy Hand Over Fist Right Now
These proven wealth builders could be exactly what you're searching for right now.
Motley Fool•Analysts revamp Microsoft stock price target after earnings
Here's what could happen next to Microsoft shares.
TheStreet•Housing supply surges by up to 50% in these metro areas — and many sellers are being forced to slash their asking prices
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
MarketWatch•Bank of America lays out the exact scenario that could finally pop the stock market's AI bubble
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Business Insider•U.S. panic over national debt might mark a culture shift—are Americans becoming more ‘European’ about money?
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Fortune•Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
Put your money to work by investing in these three high-quality dividend stocks.
Motley Fool•If I Had to Construct a Portfolio of Just 5 ETFs, Here's Exactly What I'd Buy Right Now
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
Motley Fool•Departing top Tesla exec cashes out almost his entire stake for $181 million as longtime bull Ron Baron calls bottom in the stock
Baron, whose largest position is in Tesla, is betting the new shift in strategy for Tesla’s low-cost car will fill its increasingly empty factories.
Fortune•